Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28935568
Publication Date : 2017/09/22

Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.


Oncolytic virotherapy is a promising novel approach that overcomes the limitations posed by radiation and chemotherapy. In this study, the oncolytic efficacy of a recombinant Newcastle disease virus (rNDV) BC-KLQL-GFP, against prostate cancer stem-like/tumor initiating cells was evaluated. Xenograft derived prostaspheres (XPS) induced tumor more efficiently than monolayer cell derived prostaspheres (MCPS) in nude mice. Primary and secondary XPS show enhanced self-renewal and clonogenic potential compared to MCPS. XPS also expressed embryonic stem cell markers, such as Nanog, CD44 and Nestin. Further, prostate specific antigen (PSA) activated recombinant Newcastle Disease Virus (rNDV) was selectively cytotoxic to tumor derived DU145 prostaspheres. An effective concentration (EC50) of 0.11-0.14 multiplicity of infection was sufficient to cause prostasphere cell death in serum free culture. DU145 tumor xenograft derived prostaspheres were used as tumor surrogates as they were enriched for a putative tumor initiating cell population. PSA activated rNDV was efficient in inducing cell death of cells and prostaspheres derived from primary xenografts ex-vivo, thus signifying a potential in vivo efficacy. The EC50 (∼0.1 MOI) for cytolysis of tumor initiating cells was slightly higher than that was required for the parental cell line, but within the therapeutic margin for safety and efficacy.

Authors : Raghunath Shobana , Pudupakam Raghavendra Sumanth , Allen Adria , Biswas Moanaro , Sriranganathan Nammalwar ,

Related products :

Catalog number Product name Quantity
SCH-MCA2822 MOUSE ANTI NEWCASTLE DISEASE VIRUS, Product Type Monoclonal Antibody, Specificity NEWCASTLE DISEASE VIRUS, Target Species Viral, Host Mouse, Format Purified, Isotypes IgG2a, Applications E, Clo 0.2 mg
MCA2822 MOUSE ANTI NEWCASTLE DISEASE VIRUS, Product Type Monoclonal Antibody, Specificity NEWCASTLE DISEASE VIRUS, Target Species Viral, Host Mouse, Format Purified, Isotypes IgG2a, Applications E, Clo 0.2 mg
MCA2670 MOUSE ANTI NEWCASTLE DISEASE VIRUS, Product Type Monoclonal Antibody, Specificity NEWCASTLE DISEASE VIRUS, Target Species Viral, Host Mouse, Format Purified, Isotypes IgG1, Applications E, Clon 0.2 mg
SCH-MCA2670 MOUSE ANTI NEWCASTLE DISEASE VIRUS, Product Type Monoclonal Antibody, Specificity NEWCASTLE DISEASE VIRUS, Target Species Viral, Host Mouse, Format Purified, Isotypes IgG1, Applications E, Clon 0.2 mg
orb90600 Newcastle disease virus antigen rapid test card Newcastle disease virus antigen rapid test card is a rapid test kit. The kit comes with 50 strips. For research use only. 50 tests
FR 032 > Newcastle disease virus 100 reactions
orb81809 Dengue Virus Subtype-1 Envelope 22kDa protein The E.coli derived recombinant 23 kDa protein is genetically engineered peptide which is derived from Dengue Type-1 N-terminus Envelope immunodeterminant 100
orb81825 Dengue Virus Subtype Envelope 15kDa, C-Terminal (Domain III) protein The E.coli derived recombinant 11 kDa protein is genetically engineered peptide which is derived from Dengue Type-4 envelope III do 100
orb81822 Dengue Virus Subtype Envelope 15kDa, C-Terminal (Domain III) protein The E.coli derived recombinant 11 kDa protein is genetically engineered peptide which is derived from Dengue Type-1 envelope III do 100
orb81824 Dengue Virus Subtype Envelope 15kDa, C-Terminal (Domain III) protein The E.coli derived recombinant 11 kDa protein is genetically engineered peptide which is derived from Dengue Type-3 envelope III do 100
orb81812 Dengue Virus Subtype-4 Envelope 22kDa protein The E.coli derived recombinant 28 kDa protein is genetically engineered peptide which is derived from Dengue Type-4 Envelope. This region also contains co 100
orb81811 Dengue Virus Subtype-3 Envelope 22kDa protein The E.coli derived recombinant 28 kDa protein is genetically engineered peptide which is derived from Dengue Type-3 Envelope. This region also contains co 100
orb81810 Dengue Virus Subtype-2 Envelope 22kDa protein The E.coli derived recombinant 28 kDa protein is genetically engineered peptide which is derived from Dengue Type-2 Envelope. This region also contains co 100
orb81823 Dengue Virus Subtype Envelope 15 kDa, C-Terminal (Domain III) protein The E.coli derived recombinant 11 kDa protein is genetically engineered peptide which is derived from Dengue Type-2 envelope III d 100
5-NDV Newcastle disease virus (NDV), antibody 200ug
C86012M MAb to Newcastle Disease Virus 1mg
C01352M MAb to Newcastle Disease Virus 1mg
C01351M MAb to Newcastle Disease Virus 1mg
3ND5-8H2 Newcastle disease virus 1 mg
3ND5-2H4 Newcastle disease virus 1 mg
3ND5-8H2 Newcastle disease virus 1 mg
3ND5 Newcastle disease virus 1mg
5-NDV Newcastle disease virus (NDV), antibody 500ug
3ND5-9C6 Newcastle disease virus 1 mg
3ND5-9F7 Newcastle disease virus 1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur